Evidence map›Paper›PMID 30257702›Full record

ArticleStem cell research & therapy2018

The effect of acute respiratory distress syndrome on bone marrow-derived mesenchymal stem cells.

Ben Antebi, Kerfoot P Walker, Arezoo Mohammadipoor, Luis A Rodriguez, Robbie K Montgomery, Andriy I Batchinsky, Leopoldo C Cancio

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Mesenchymal Stromal Cells in Acute Respiratory Distress Syndrome: More Questions Than Answers.American journal of respiratory and critical care medicine · 2023
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ben AntebiUnited States Army Institute of Surgical Research, San Antonio, TX, USA. ben.antebi.ctr@mail.mil.ORCID 0000-0002-2062-5206
Kerfoot P WalkerUnited States Army Institute of Surgical Research, San Antonio, TX, USA.
Arezoo MohammadipoorUnited States Army Institute of Surgical Research, San Antonio, TX, USA.
Luis A RodriguezUnited States Army Institute of Surgical Research, San Antonio, TX, USA.
Robbie K MontgomeryUnited States Army Institute of Surgical Research, San Antonio, TX, USA.
Andriy I BatchinskyUnited States Army Institute of Surgical Research, San Antonio, TX, USA.
Leopoldo C CancioUnited States Army Institute of Surgical Research, San Antonio, TX, USA.
United States Army Institute of Surgical Research · USOak Ridge Associated Universities · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is known that, following a physiological insult, bone marrow-derived mesenchymal stem cells (MSCs) mobilize and home to the site of injury. However, the effect of injury on the function of endogenous MSCs is unknown. In this study, MSCs harvested from the bone marrow of swine with or without acute respiratory distress syndrome (ARDS) were assessed for their characteristics and therapeutic function.

methodsMSCs were harvested from three groups of anesthetized and mechanically ventilated swine (n = 3 in each group): 1) no ARDS ('Uninjured' group); 2) ARDS induced via smoke inhalation and 40% burn and treated with inhaled epinephrine ('Injured Treated' group); and 3) ARDS without treatment ('Injured Untreated' group). Cellular evaluation of the three groups included: flow cytometry for MSC markers; colony forming unit-fibroblast (CFU-F) assay; proliferative and metabolic capacity; gene expression using quantitative real-time polymerase chain reaction (qRT-PCR); and a lipopolysaccharide (LPS) challenge, with or without coculture with mononuclear cells (MNCs), for evaluation of their protein secretion profile using Multiplex. Statistical analysis was performed using one- or two-way analysis of variance (ANOVA) with a Tukey's post-test; a p-value less than 0.05 was considered statistically significant.

resultsCells from all groups exhibited nearly 100% expression of MSC surface markers and retained their multidifferentiation capacity. However, the MSCs from the 'Injured Untreated' group generated a significantly higher number of colonies compared with the other two groups (p < 0.0001), indicative of increased clonogenic capacity following ARDS. Following an LPS challenge, the MSCs from the 'Injured Untreated' group exhibited a significant reduction in their proliferative capacity (p = 0.0002), significant downregulation in the expression of high-mobility group box 1 (HMGB1; p < 0.001), Toll-like receptor (TLR)-4 (p < 0.01), and vascular endothelial growth factor (VEGF; p < 0.05) genes, and significantly diminished secretory capacity for the inflammatory mediators interleukin (IL)-6 (p < 0.0001), IL-8 (p < 0.05), and tumor necrosis factor (TNF)-α (p < 0.05) compared with the 'Uninjured' group.

conclusionsThe results suggest that, following ARDS, there is an increase in the clonogenic capacity of MSCs to increase the available stem cell pool in vivo. However, MSCs harvested from subjects with ARDS seem to exhibit a diminished capacity to proliferate, express regenerative signals, and secrete pro/anti-inflammatory mediators.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsBone Marrow CellsCoculture TechniquesFlow CytometryGene Expression RegulationHMGB1 ProteinLipopolysaccharidesMesenchymal Stem CellsRespiratory Distress SyndromeSwineToll-Like Receptor 4Tumor Necrosis Factor-alphaHMGB1 ProteinLipopolysaccharidesToll-Like Receptor 4Tumor Necrosis Factor-alphaAcute respiratory distress syndrome (ARDS)Autologous therapyBone marrowImmunomodulationInjuryMesenchymal stem cells (MSCs)

Identifiers

PMID30257702
PMCPMC6158906
OpenAlexW2892887190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.